The drug discovery of converting antibody to small molecule drug (PD-L1 inhibitor)

DOI
  • Miyazaki Susumu
    Chemical Research Laboratories, Central Pharmaceutical Research Institute Takatsuki Research Center, JAPAN TOBACCO INC.
  • Hantani Yoshiji
    Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute Takatsuki Research Center, JAPAN TOBACCO INC.
  • Kawashita Seiji
    Chemical Research Laboratories, Central Pharmaceutical Research Institute Takatsuki Research Center, JAPAN TOBACCO INC.

Bibliographic Information

Other Title
  • 抗体医薬の低分子創薬（PD-L1阻害薬）

Search this article

Description

<p>Blocking the immune checkpoint receptor (PD-1) or its ligand (PD-L1) with antibodies has proven to be an effective treatment for multiple cancer types, and the success of this cancer immunotherapy has led to a paradigm shift in cancer treatment. The drug discovery aimed at inhibiting the target proteins, whose pharmacological outcomes are proven to be effective with the antibody, with inexpensive and orally available small-molecule drugs has a high hurdle to overcome, but are of great significance. In this article, we will introduce various approaches to drug discovery that are unique to small molecules, which demonstrate a different mechanism of action from those of antibodies and have similar drug effects to those of antibodies.</p>

Journal

  • MEDCHEM NEWS

    MEDCHEM NEWS 31 (1), 30-35, 2021-02-01

    The Pharmaceutical Society of Japan

Keywords

Details 詳細情報について

Report a problem

Back to top